Inhibition of NF1 Protein Degradation as a Treatment for NF1 Haploinsufficiency
抑制 NF1 蛋白降解作为 NF1 单倍体不足的治疗方法
基本信息
- 批准号:10490386
- 负责人:
- 金额:$ 14.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-20 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAgeAllelesAmericanAnimalsBiological AssayCell LineCell ProliferationCellsClustered Regularly Interspaced Short Palindromic RepeatsComplexCutaneousCyclic AMPDNA Sequence AlterationDataDetectionDevelopmentDisease ProgressionDominant Genetic ConditionsDoseELK1 geneEngineeringEnvironmentEnzyme-Linked Immunosorbent AssayEvaluationFRAP1 geneFibroblastsGene MutationGenesGeneticGenetic DiseasesGenetic ScreeningGenomeGenotypeGoalsGrowth FactorHCN1 geneHalf-LifeHeterozygoteHumanHypoxiaIn VitroIndividualInvestigationLibrariesLinkLuciferasesMEK inhibitionMEKsModificationMutateMutationNF1 geneNeurofibromatosesNeurofibromatosis 1OrphanOther GeneticsPathologyPathway interactionsPatientsPersonsPharmaceutical PreparationsPhasePhenotypePlant RootsPlayPreventive treatmentProteinsProteomicsProto-Oncogene Proteins c-aktPublishingRas Signaling PathwayReaction TimeReporterResearchResearch InstituteResearch PersonnelRiskRoleSafetySchwann CellsSerumSignal TransductionSmall Business Innovation Research GrantSmall Interfering RNASupravalvular aortic stenosisSymptomsTherapeuticTissuesTranscendTransfectionUbiquitin-Activating EnzymesUbiquitin-Conjugating EnzymesUbiquitinationWilliams SyndromeYangassociated symptombasebrain pathwaycell typecommercializationdrug candidatedrug discoverydrug repurposinggene therapyhigh throughput screeningimprovedin vivoin vivo Modelinduced pluripotent stem cellinhibitorinnovationknock-downmedication safetyneurofibromanovelnovel therapeuticsprogramsprotein degradationprotein expressionscreeningsmall moleculesmall molecule librariessuccesstooltranscription factortumortumor progressionubiquitin ligase
项目摘要
PROJECT ABSTRACT. Haploinsufficiency plays a crucial role in Neurofibromatosis (NF1), an autosomal
dominant genetic disorder impacting over 120,000 Americans. Current therapeutic approaches target
downstream components of NF1 signaling, for example MEK inhibition in tumors, thus failing to address the
broad range of signaling and symptoms associated with NF1 mutations. Given that NF1 is characterized by
both autosomal dominance and haploinsufficiency (lack of normal protein), inhibiting NF1 protein degradation,
causing a net increase in NF1 protein, has the potential to alleviate a broad range of NF1 symptoms and halt
overall disease progression. Infixion proposes to identify and validate genes involved in NF1 protein
ubiquitination and degradation, and to build a protein-tagged reporter assay to screen the impact of known
drugs on NF1 protein levels, with a focus on modulators of NF1 protein degradation. By identifying candidate
drugs inhibiting NF1 ubiquitination, we target an increase in overall NF1 protein, and thus a normalizing of Ras
(and other) pathway signaling in individuals with NF1. We propose this as a novel path of NF1 drug discovery,
with potential impact on a broad range of NF1 patients and symptoms, in a preventative manner, and
applicable to the very wide spectrum of unique NF1 genetic mutations.
Research Background. Increasing NF1 expression via transfection reverses abnormal Ras activation
resulting from NF1 loss (Wallis, 2018; Mellert, 2018). Increased protein expression in other genetic conditions
such as Willams-Beuren Syndrome, and Supravalvular Aortic Stenosis compensates for haploinsufficiency
(Giordano, et al. 2012). Lastly, overcoming haploinsufficiency in other autosomal dominant conditions (Sim1;
Pax6 genes) have shown an ability in vivo to correct symptoms. (Matharu, et. al. 2019; Rabiee, et. al. 2020).
Specific Aims. 1) Identify regulators of NF1 protein stability using siRNA libraries as a genetic (knock-down)
screen in NF1-relevant cell types. Identifying regulators of NF1 ubiquitination and subsequent degradation will
allow for rational selection of additional libraries to screen for compounds to increase NF1 protein. 2) Construct
an assay, engineering the endogenous NF1 gene to tag the NF1 protein, in a well characterized, publicly
available (ATCC), immortalized NF1 +/- Schwann cell line. Validate assay using compounds already verified by
Infixion to increase NF1 protein levels. 3) Deploy NF1 protein stabilization assay to screen a 13,000+
compound repurposing library of known drugs available from Scripps Research Institute (known as ReFrame),
and other targeted libraries. The top hits from these screens will be evaluated utilizing immortalized Schwann,
primary fibroblast and iPSC derived NF1+/- cells, for the following: a) ability to induce NF1 protein expression
using Westerns/ELISA, b) impact on Ras signaling (pERK, ELK-1, AKT, etc.) utilizing a targeted quantitative
mass spec proteomics assay, c) impact on cell proliferation, and d) safety profile based on published data.
Program goal is to prioritize 3-5 candidate compounds for an SBIR Phase 2 pre-IND evaluation.
项目摘要。单倍体功能不全在常染色体神经纤维瘤病(NF1)中起着关键作用
影响超过12万美国人的显性遗传病。当前治疗方法的靶向
NF1信号的下游成分,例如肿瘤中的MEK抑制,因此未能解决
与NF1突变相关的广泛的信号和症状。鉴于NF1的特点是
常染色体显性和单倍体不足(缺乏正常蛋白质),抑制NF1蛋白的降解,
导致NF1蛋白的净增加,有可能缓解广泛的NF1症状并停止
总的疾病进展。Infix建议识别和验证与NF1蛋白相关的基因
泛素化和降解,并建立蛋白质标记的报告实验来筛选已知的影响
药物对NF1蛋白水平的影响,重点是NF1蛋白降解的调节剂。通过确定候选人
抑制NF1泛素化的药物,我们的目标是增加总体NF1蛋白,从而使RAS正常化
NF1患者的(和其他)途径信号。我们提出这是NF1药物发现的一条新途径,
以预防性的方式,对广泛的NF1患者和症状产生潜在影响,以及
适用于非常广泛的独特的NF1基因突变。
研究背景。通过转基因提高NF1的表达逆转RAS的异常激活
由NF1的损失造成(Wallis,2018;Mellert,2018)。在其他遗传条件下蛋白质表达增加
如Willams-Beuren综合征和瓣膜上动脉狭窄补偿单倍体功能不全
(Giordano,et al.2012年)。最后,克服其他常染色体显性条件下的单倍体不足(Sim1;
Pax6基因)在体内显示出纠正症状的能力。Matharu等人艾尔2019年;et Rabiee艾尔2020)。
明确的目标。1)使用siRNA文库识别NF1蛋白稳定性的调节因子作为基因(敲除)
筛选出与NF1相关的细胞类型。确定NF1泛素化和随后降解的调节因子将
允许合理选择额外的文库以筛选增加NF1蛋白的化合物。2)构造
一种试验,设计内源性nf1基因来标记nf1蛋白,在一种具有良好特征的公开
可获得(ATCC)、永生化的NF1+/-雪旺细胞系。使用已由以下机构验证的化合物进行验证
固定可提高NF1蛋白水平。3)部署NF1蛋白稳定试验,筛选出13,000+
从斯克里普斯研究所获得的已知药物的化合物再用途文库(称为ReFrame),
和其他目标库。来自这些屏幕的最高点击量将使用不朽的施万恩进行评估,
原代成纤维细胞和IPSC来源的NF1+/-细胞,用于以下方面:a)诱导NF1蛋白表达的能力
使用Westns/ELISA,b)对RAS信号的影响(PERK、ELK-1、AKT等)利用有针对性的数量
质谱学蛋白质组学分析,c)对细胞增殖的影响,d)基于已公布数据的安全性概况。
该计划的目标是为SBIR第二阶段Pre-IND评估确定3-5个候选化合物的优先级。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michelle Mattson-Hoss其他文献
Michelle Mattson-Hoss的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michelle Mattson-Hoss', 18)}}的其他基金
Steric-blocking AntiSense Oligonucleotide (ASO) Discovery to Selectively Correct NF1 Haploinsufficiency
发现立体阻断反义寡核苷酸 (ASO) 以选择性纠正 NF1 单倍体不足
- 批准号:
10546542 - 财政年份:2022
- 资助金额:
$ 14.38万 - 项目类别:
Steric-blocking AntiSense Oligonucleotide (ASO) Discovery to Selectively Correct NF1 Haploinsufficiency
发现立体阻断反义寡核苷酸 (ASO) 以选择性纠正 NF1 单倍体不足
- 批准号:
10844204 - 财政年份:2022
- 资助金额:
$ 14.38万 - 项目类别:
Steric-blocking AntiSense Oligonucleotide (ASO) Discovery to Selectively Correct NF1 Haploinsufficiency
发现立体阻断反义寡核苷酸 (ASO) 以选择性纠正 NF1 单倍体不足
- 批准号:
10752193 - 财政年份:2022
- 资助金额:
$ 14.38万 - 项目类别:
Steric-blocking AntiSense Oligonucleotide (ASO) Discovery to Selectively Correct NF1 Haploinsufficiency
发现立体阻断反义寡核苷酸 (ASO) 以选择性纠正 NF1 单倍体不足
- 批准号:
10789739 - 财政年份:2022
- 资助金额:
$ 14.38万 - 项目类别:
Inhibition of NF1 Protein Degradation as a Treatment for NF1 Haploinsufficiency
抑制 NF1 蛋白降解作为 NF1 单倍体不足的治疗方法
- 批准号:
10325710 - 财政年份:2021
- 资助金额:
$ 14.38万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 14.38万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 14.38万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 14.38万 - 项目类别:
Fellowship
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 14.38万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 14.38万 - 项目类别:
Continuing Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 14.38万 - 项目类别:
Standard Grant
The economics of (mis)information in the age of social media
社交媒体时代(错误)信息的经济学
- 批准号:
DP240103257 - 财政年份:2024
- 资助金额:
$ 14.38万 - 项目类别:
Discovery Projects
How age & sex impact the transcriptional control of mammalian muscle growth
你多大
- 批准号:
DP240100408 - 财政年份:2024
- 资助金额:
$ 14.38万 - 项目类别:
Discovery Projects
Supporting teachers and teaching in the age of Artificial Intelligence
支持人工智能时代的教师和教学
- 批准号:
DP240100111 - 财政年份:2024
- 资助金额:
$ 14.38万 - 项目类别:
Discovery Projects
Enhancing Wahkohtowin (Kinship beyond the immediate family) Community-based models of care to reach and support Indigenous and racialized women of reproductive age and pregnant women in Canada for the prevention of congenital syphilis
加强 Wahkohtowin(直系亲属以外的亲属关系)以社区为基础的护理模式,以接触和支持加拿大的土著和种族育龄妇女以及孕妇,预防先天梅毒
- 批准号:
502786 - 财政年份:2024
- 资助金额:
$ 14.38万 - 项目类别:
Directed Grant